Frankfurt - Delayed Quote EUR

AIM ImmunoTech Inc. (HXB2.F)

0.0610
0.0000
(0.00%)
At close: April 4 at 3:50:39 PM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Thomas K. Equels Esq., J.D., M.S. Executive Vice Chairman, CEO & President 795.73k -- 1953
Mr. Robert Dickey IV, M.B.A. Chief Financial Officer 44.31k -- 1956
Mr. Peter W. Rodino III, Esq., J.D. COO, Executive Director of Governmental Relations, General Counsel & Secretary 421.55k -- 1951
Dr. Christopher McAleer Ph.D. Scientific Officer -- -- --
Ann Marie E. Coverly Director of Administration & Human Resources and Deputy Investor Relations Coordinator -- -- --
Dr. Ralph Christopher Cavalli Ph.D. Vice President of QC & Manufacturing 209.99k -- 1958

AIM ImmunoTech Inc.

2117 SW Highway 484
Ocala, FL 34473
United States
352 448 7797 https://aimimmuno.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
21

Description

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Corporate Governance

AIM ImmunoTech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 14, 2025 at 12:30 PM UTC - August 18, 2025 at 12:30 PM UTC

AIM ImmunoTech Inc. Earnings Date

Recent Events

Related Tickers

ACHV Achieve Life Sciences, Inc.
3.0800
+12.82%
 
PTNT Palatin Technologies, Inc.
0.1300
-13.33%
 
HEPA Hepion Pharmaceuticals, Inc.
0.3180
0.00%
 
OTLK Outlook Therapeutics, Inc.
1.7500
+4.48%
 
ATOS Atossa Therapeutics, Inc.
0.9701
-1.57%